Literature DB >> 25747699

How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977-2014.

John A Ellis1.   

Abstract

Bordetella bronchiseptica (Bb) has long been causally associated with respiratory disease in dogs. Parenteral and intranasal vaccines for this pathogen have been in common use since their development in the late 1970s and early 1980s and recently a commercial oral Bb vaccine has become available. Overall, the literature (comprising experimental infection models and field studies) documents the efficacy of these vaccines in stimulating disease-sparing mucosal and systemic immune responses that can be associated with reduced growth of Bb in vivo. However, many of the published studies are limited by flaws in experimental design, most notably a failure to consider the biological and statistical implications of the 'pen effect'. Many questions related to the longevity of vaccine induced immunity against Bb and the impact of natural exposure on herd immunity remain unanswered.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bordetella bronchiseptica; Canine infectious respiratory disease; Dogs; Injectable vaccine; Intra-nasal vaccine; Kennel cough; Oral vaccine

Mesh:

Substances:

Year:  2015        PMID: 25747699     DOI: 10.1016/j.tvjl.2015.02.006

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  17 in total

1.  Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.

Authors:  D Bottero; M E Zurita; M E Gaillard; E Bartel; C Vercellini; D Hozbor
Journal:  Appl Environ Microbiol       Date:  2018-01-31       Impact factor: 4.792

2.  Oral Application of Recombinant Bacillus subtilis Spores to Dogs Results in a Humoral Response against Specific Echinococcus granulosus Paramyosin and Tropomyosin Antigens.

Authors:  Cédric M Vogt; Maria Teresa Armúa-Fernández; Kurt Tobler; Monika Hilbe; Claudio Aguilar; Mathias Ackermann; Peter Deplazes; Catherine Eichwald
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

3.  WSAVA Guidelines for the vaccination of dogs and cats.

Authors:  M J Day; M C Horzinek; R D Schultz; R A Squires
Journal:  J Small Anim Pract       Date:  2016-01       Impact factor: 1.522

4.  The Bordetella Bps Polysaccharide Is Required for Biofilm Formation and Enhances Survival in the Lower Respiratory Tract of Swine.

Authors:  Tracy L Nicholson; Susan L Brockmeier; Neelima Sukumar; Alexandra E Paharik; Jessica L Lister; Alexander R Horswill; Marcus E Kehrli; Crystal L Loving; Sarah M Shore; Rajendar Deora
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Bordetella Colonization Factor A (BcfA) Elicits Protective Immunity against Bordetella bronchiseptica in the Absence of an Additional Adjuvant.

Authors:  Kacy S Yount; Jamie Jennings-Gee; Kyle Caution; Audra R Fullen; Kara N Corps; Sally Quataert; Rajendar Deora; Purnima Dubey
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

6.  Conditional growth defect of Bordetella pertussis and Bordetella bronchiseptica ferric uptake regulator (fur) mutants.

Authors:  Eline F de Jonge; Jan Tommassen
Journal:  FEMS Microbiol Lett       Date:  2022-07-01       Impact factor: 2.820

7.  Comparative efficacy of intranasal and injectable vaccines in stimulating Bordetella bronchiseptica-reactive anamnestic antibody responses in household dogs.

Authors:  John A Ellis; Sheryl P Gow; Lindsey B Lee; Stacey Lacoste; Eileen C Ball
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

8.  Bordetella bronchiseptica-reactive antibodies in Canadian polar bears.

Authors:  John Ellis; Sheryl Gow; Nicholas Pilfold; Stacey Lacoste; Nicholas J Lunn; Evan S Richardson; David McGeachy; Megan Owen; Bruce Rideout
Journal:  Can Vet J       Date:  2021-07       Impact factor: 1.008

9.  Reduction of endotoxicity in Bordetella bronchiseptica by lipid A engineering: Characterization of lpxL1 and pagP mutants.

Authors:  Jesús Pérez-Ortega; Roel M Van Harten; Ria Van Boxtel; Michel Plisnier; Marc Louckx; Dominique Ingels; Henk P Haagsman; Jan Tommassen
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

10.  Comparative onset of immunity of oral and intranasal vaccines against challenge with Bordetella bronchiseptica.

Authors:  Maya M Scott-Garrard; Yu-Wei Chiang; Frederic David
Journal:  Vet Rec Open       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.